Introduction {#s1}
============

Inflammatory bowel disease (IBD) is a multifactorial complex illness which principally consists of ulcerative colitis and Crohn's disease. Physiologically, the human body ensures the removal of detrimental stimuli through inflammation, nevertheless, several outcomes such as tissue damage may take place with an uncontrolled inflammation response which must be tightly controlled ([@B25]). In order to validate potential treatments in preclinical settings and decipher the pathogenesis of IBD, a series of mouse colitis models have been developed as indispensable tools. Usually, the colitis mouse model induced by dextran sulfate sodium (DSS) has been used extensively in human ulcerative colitis research due to its fast, flexible, reproducibility and controllability ([@B26]). The DSS acts as a negatively charged water-soluble sulfated polysaccharide with a highly variable molecular weight ranging from 5 to 1,400 kDa ([@B6]). Through the alteration in the concentration and the frequency of DSS administration, acute, chronic, and relapsing models of intestinal inflammation may be achieved ([@B9]; [@B30]). Notably, a closely resembled human ulcerative colitis (UC) is regarded as the most severe murine colitis that is induced through the administration of 40 to 50 kDa DSS in drinking water ([@B31]). Pathomechanistically, DSS may induce inflammation *via* activation of transcription factor nuclear factor kappa B (NF-κB) signaling pathway, which is principally localized in the colon with characteristics such as ulceration, damage in epithelial cells, hyperplasia in lymphoid cells, and inflammatory infiltration in mucosa cells.

Actually, continuous or discontinuous mucosal inflammation, ulceration of the mucosa epithelial, cell destruction, and ulceration of most intestine and/or colon ([@B57]) characterized both UC and Crohn's diseases. Based on existing evidence, immune responses that are elicited by inflammatory cell infiltration, especially macrophages are associated with IBD ([@B34]; [@B49]). Macrophages are reported to be central mediators of innate immune homeostasis and inflammation, which can migrate to the inflamed colonic mucosa and release active metabolites of oxygen, nitrogen, and proteases for the degradation of the extracellular matrix ([@B15]). Different microenvironment stimulation has been reported to trigger macrophages polarization into inflammatory M1 phenotype and anti-inflammatory M2 ([@B16]; [@B23]). The M1 macrophages, usually act as efficient effector cells in the response to microbial products or interferon-gamma (IFN-γ) ([@B2]), and is characterized by high levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) ([@B4]), nitric oxide (NO), and reactive oxygen species (ROS) intermediates. This process therefore promotes polarized type I immune responses by mediating host defense against bacterial, protozoal, and tumor cell infections ([@B12]; [@B37]). The M2 macrophages are involved in the regression of inflammation, and are usually activated by interleukin (IL)-4 and IL-10 amidst their involvement in tissue repair and remodeling processes ([@B51]; [@B47]). Some studies have shown that M1 macrophages increased in colitis, while M2 macrophages decreased under the same condition culminating in phenotypic imbalance of macrophages, which further promoted the development of colitis ([@B10]; [@B36]). Pertinently, the switching of M1 to M2 macrophages could decrease colitis ([@B43]), indicating that the regulation of macrophages polarization could act as the emerging targets for IBDs therapy ([@B21]; [@B54]; [@B55]).

As a very valuable herb, *Ginkgo biloba*, has been used as a traditional herbal medicine (TCM) for the past several thousand years. *G. biloba* leaf extracts showed a variety of biological activities, mostly against cardiovascular and neurological diseases ([@B45]; [@B32]; [@B50]; [@B3]). Recently, many studies have hinted that anti-inflammation activity contributed to the improvement of cardiovascular and neurological diseases by *G. biloba* leaf extracts. The *G. biloba* extract reduced hippocampus inflammatory responses and improved cardiac functions and depressive behaviors in a heart failure mouse model ([@B52]). The *G. biloba* inhibited hydrogen peroxide induced activation of NF-κB in vascular endothelial cell ([@B44]) and inhibited cerebral ischemia/reperfusion induced inflammatory response in astrocytes *via* TLR4/NF-κB pathway in rats ([@B20]). The extracts also showed high inhibition of TNF-*α*-induced vascular cell adhesion molecule-1 (VCAM-1) release, which was partly due to the NF*-*κB pathway impairment ([@B33]).

Moreover, the anti-inflammatory activities of *G. biloba* extract was gradually confirmed. It has been reported that the phospholipase A2 could be inhibited by the extract of *G. biloba* leaves, wherein the extracted compound showed the potent antiarthritic activity in rat adjuvant-induced arthritis ([@B27]). There is also evidence for an anti-inflammatory function of *G. biloba* extract, with reports that *G. biloba* inhibited formalin and carrageenan-induced paw edema and reduced experimentally induced uveitis in rats ([@B1]; [@B14]). These anti-inflammatory properties of *G. biloba* are suggested to be mediated through inhibition of a range of proinflammatory mediators including NO, IL-1β and tumor necrosis factor α (TNF-α) ([@B40]; [@B17]; [@B8]; [@B41]; [@B14]). There is a unique sesquiterpene trilactone constituent (bilobalide) in *G. biloba* which has shown anti-inflammatory properties *via* lowering production in of some inflammatory cytokines ([@B11]). However, extensive literature and patent searches indicate that there is data scarcity on the effect of bilobalide on colitis

Herein, the effect of bilobalide on macrophages polarization in murine RAW264.7 cell line was analyzed, while the effect on DSS-induced colitis was evaluated. Through *in vitro* and *in vivo* experiments, bilobalide was hypothesized to exert its anti-inflammatory activities in colitis by inhibiting macrophages M1 polarization *via* suppression of NF-κB signaling pathway.

Materials and Method {#s2}
====================

Animals {#s2_1}
-------

C57BL/6 mice (female, 6--8 weeks old, 18--22 g) were purchased from the Laboratory Animal Centre of Jiangsu University (Zhenjiang, China). The mice were grouped randomly at specific-pathogen-free (SPF) facility, while the temperature was controlled at 22 ± 2°C and the lighting conditions were constantly circulated in 12 h of light and 12 h of darkness. The animal experiments were approved by Animal Experimental Ethical Committee of Southeast University and carried out at Laboratory Animal Research Centre of Jiangsu University (NO. 2018--0553). Every effort was made to reduce the number of animals used coupled with minimizing the suffering of the animals.

Reagents {#s2_2}
--------

Bilobalide (S2276, 99.09% purity) was obtained from Selleck Co. Ltd. (Shanghai, China). Bilobalide was dissolved in dimethyl sulfoxide (DMSO) at 30 mM as a stock solution for *in vitro* experiment. It was diluted with culture medium when used and the some concentration of DMSO was used as vehicle control. As for animal administration, bilobalide were dissolved in the sodium salt of carboxymethyl cellulose (CMC-Na, 0.9%). Lipopolysaccharide (LPS, L2630) was bought from Sigma-Aldrich (St. Louis, MO, USA). The DSS was provided by MP Biomedical (molecular weight 36,000--50,000, MP Biomedical ICN, France). Roswell Park Memorial Institute Medium (RPMI)-1640 and fetal bowel serum were supplied by from Life Technology (Carlsbad, CA, USA). Antibody for CD11C-pecy5 (15-0114-82), MHC-II-PE (12-0920-82) was obtained from eBioscience (San Diego, CA, USA). Recombinant murine IFN-γ (315-05) and macrophage-colony stimulating factor (M-CSF, 315-03) were provided by PeproTech (Rocky Hill, NJ). Antibodies for p-p65 (3033) and p65 (8242) were bought from Cell Signaling Technology (Beverly, MA, USA). Antibodies for p-STAT1 (9167) and STAT1 (14994) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488 goat anti-rabbit IgG (A-31565) and 4′, 6-diamidino-2-phenylindole (DAPI) were provided by Invitrogen (Carlsbad, CA). The ELISA kit for murine TNF-α (70-EK282/3-96), IL-1β (70-EK201B/3-96), and IL-6 (70-EK206/3-96) were procured from Multi-Science Co. Ltd. (Hangzhou, China). Annexin V/PI staining kit (70-AP101-100) was bought from Multi-Science Co. Ltd. (Hangzhou, China). Antibody for Actin (sc-8432) was purchased from Santa Cruz (Santa Cruz, CA, USA). All other chemicals were supplied by Sigma-Aldrich (St. Louis, MO, USA).

Cell Culture {#s2_3}
------------

Murine Raw 264.7 cells were obtained from the American Type Culture Collection (Rockville, MD). The cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS, Gibco, Grand Island, NY), 100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO2 at 37°C. Human monocytic THP-1 cell line was purchased from the American Type Culture Collection (Rockville, MD) and cultured in RPMI1640 (Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS, Gibco, Grand Island, NY), 100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO2 at 37°C. Bone marrow-derived macrophages (BMDMs) were prepared by minor changes based on previous work ([@B38]). In brief, 21-ga needle was used to flush femurs using PBS. Medium comprising 10% FBS RPMI 1640 was prepared. The cells were cultured in the aforementioned medium at 37°C in 5% CO2 for 5 days. The adherent macrophages were washed twice with PBS, prior to culturing of the cells with fresh DMEM medium composing of 10% FBS and 10 ng/ml LPS and 10 ng/ml IFN-γ (M1-polarization) for 6 h.

Quantitative Polymerase Chain Reaction (qPCR) {#s2_4}
---------------------------------------------

TRIzol (Invitrogen, Carlsbad, CA) was used to isolate total RNA from cells or tissues. Total RNA reverse was transcribed to complementary DNA (cDNA) and subjected to quantitative PCR *via* ABI 7500 detection system (Applied Biosystems, CA) using ChamQ Universal SYBR qPCR Master Mix (Vazyme, China). Bio-Rad CFX Manager Software was then applied to obtain threshold cycle numbers. The amplification program was 2 min at 95°C for 1 cycle followed by 10 s at 95°C for 40 cycle, 30 s at 60°C, and then 30 s at 72°C. Next, β-actin was used as endogenous control to normalize the entire sample's difference in total RNA. Comparative CT method also referred to as 2^−ΔΔCT^ method, i.e., fold change = 2^−ΔΔCT^ = \[(C~T~ gene of interest − C~T~ gene of actin control) sample A − (C~T~ gene of interest − C~T~ gene of actin control) sample B\] was applied to calculate the relative gene expression. The primer sequences used in this study were as follows:

1.  TNF-α, 5′-CGAGTGACAAGCCTGTAGCCC-3′ (forward) and 5′-GTCTTTGAGATCCATGCCGTTG-3′ (reverse);

2.  IL-1β, 5′-CTTCAGGCAGGCAGTATCACTC-3′ (forward) and 5′-TGCAGTTGTCTAATGGGAACGT-3′ (reverse);

3.  IL-6, 5′-ACAACCACGGCCTTCCCTAC-3′ (forward) and 5′-TCTCATTTCCACGATTTCCCAG-3′ (reverse);

Cytokine Analysis by ELISA {#s2_5}
--------------------------

The ELISA kits obtained from Multi-Science Co. Ltd. (Hangzhou, China) were used to quantify the mounts of TNF-α, IL-1β, and IL-6 in the supernatant or serum from mice. Specific experimental procedures were performed according to the manufacturer's instructions.

Western Blot {#s2_6}
------------

Samples were collected and lysed in a lysis buffer containing pro-tease inhibitor (protease inhibitor cocktail, Pierce). Afterwards, 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to isolate the obtained protein lysate and then electrotransferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore Corp., Bedford, MA). At room temperature, 5% skim milk was used to seal the membrane for 1 h. Subsequently, different antibodies were incubated with the secondary antibody after incubation at 4°C overnight, after which a suitable horseradish peroxidase (HRP)-conjugated secondary antibody was added. Protein bands were visualized using a Western blot detection system according to the specifications of the manufacturer (Cell Signaling Technology, MA).

Immunofluorescent Assay {#s2_7}
-----------------------

The paraformaldehyde (4%, PFA) was used to immobilize bone marrow-derived macrophages (BMDM) on coverslips, followed by permeation with 0.5% Triton X-100 for 20 min and was finally sealed with 3% bovine serum albumin (BSA) for 30 min. The cells were immunostained with anti-p65 Ab overnight. Then, Alexa Fluor 488-conjugated anti-rabbit IgG (Life technology, CA) was immunostained for 2 h. Afterwards, DAPI was applied to counterstain the coverslips and then imaged with a confocal laser scanning microscope (Olympus, Lake Success, NY).

Flow Cytometry Analysis {#s2_8}
-----------------------

Flow cytometry analysis was performed according to standard procedures. Briefly, cold PBS was used to harvest and wash cultured cells followed by staining with specific antibodies for 30 min at 4°C in the dark. Finally, the sample was analyzed *via* flow cytometry.

Dextran Sulfate Sodium-Induced Colitis {#s2_9}
--------------------------------------

The mouse model of acute colitis was induced *via* the addition of 3% DSS to the drinking water of the animals for 7 days. The C57BL/6 mice in the control group received the same drinking water without DSS (n=6 mice per group). Next, different doses of bilobalide (1.25, 2.5, 5 mg/kg) and 5-aminosalicylic acid (5-ASA) (100 mg/kg) were dissolved in the sodium salt of carboxymethyl cellulose (CMC-Na, 0.9%). Mice in the control and model groups were administered (i.g) once a day for 10 days. The bodyweight, the consistency of the stool and the presence of gross blood in feces and at the anus were observed daily. The disease activity index was calculated by assigning well-established and validated scores ([@B22]). The degree of diarrhea and blood in the stool as an evaluation index: a) degree of diarrhea (0 points = normal, 2 points = loose stools, 4 points = watery diarrhea); b) degree of hematochezia (0 points = no bleeding, 2 points = slight bleeding, 4 points = gross bleeding). On the 10^th^ day, the animals were sacrificed and the entire colon segment used for the *ex vivo* studies was quickly removed. They were then fixed in paraffin-embedded 10% normal buffered formalin, which was subsequently stained with hematoxylin and eosin and scored using an evaluated (blind) histology (0, no signs of inflammation; 1, low leukocyte infiltration; 2, moderate leukocyte infiltration; 3, high leukocyte infiltration, moderate fibrosis, high vascular density thickening of the colon wall, moderate goblet cell loss, and focal loss of crypts; as well as 4, transmural infiltrations, massive loss of goblet cell, extensive fibrosis, and diffuse loss of crypts).

Immunohistochemical Analysis {#s2_10}
----------------------------

In order to clarify the expression of p-p65, paraffin-embedded colon tissue sections (4--5 μm) were subjected to immunohistochemical analysis. The slides were dewaxed and rehydrated, after which they were sealed and incubated with p-p65 antibody at 4°C for a whole night. Next, streptavidin-HRP was used to incubate the slides for 40 min, then stained with 3, 3′ diaminobenzidine tetrahydrochloride (DAB) substrate (Santa Cruz Biotechnology, CA) and then counter-stained with hematoxylin. The images were taken with Olympus IX81.

Statistical Analysis {#s2_11}
--------------------

All the data were presented as mean ± SEM of three independent experiments with each measurement performed in triplicate. One-way ANOVA analysis and student's t-test were used for comparison between the control groups and the various experimental groups. Student's t-test was used to compare between two groups. A P-value less than 0.05 was considered as statistically significant.

Results {#s3}
=======

Cytotoxicity of Bilobalide on Macrophages {#s3_1}
-----------------------------------------

The structure of bilobalide is shown in [**Figure 1A**](#f1){ref-type="fig"}. It was observed that at concentration of 30 μM, the functional groups of bilobalide were nontoxic to Raw 264.7 cells ([**Figure 1B**](#f1){ref-type="fig"}). Additionally, bilobalide did not inhibit the proliferation of both THP1 and BMDMs even at 30 μM ([**Figure 1B**](#f1){ref-type="fig"}). Likewise, bilobalide did not induce marked apoptosis in BMDMs ([**Figure 1C**](#f1){ref-type="fig"}). Collectively, these results indicated that bilobalide has no significant toxicity on macrophage.

![Bilobalide has no toxicity on macrophages. **(A)** Chemical structure of bilobalide. **(B)** Cell viability test of bilobalide on bone marrow-derived macrophages (BMDM), Raw 164.7, BMDM, and human monocytic leukemia cell line, THP1. The cells were incubated with various concentrations of bilobalide or the same volume of dimethyl sulfoxide (DMSO) and then tested for cell proliferation *via* 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. **(C)** The cells were treated with 3, 10, and 30 μM bilobalide or the same volume of DMSO. Next, the cells were stained with annexin V/PI and assayed *via* flow cytometry. \*P \< 0.05 and \*\*P \< 0.01 compared with the control group.](fphar-11-00718-g001){#f1}

Effects of Bilobalide on Inflammatory Cytokine Expression and Differentiation of M1 Macrophage {#s3_2}
----------------------------------------------------------------------------------------------

Based on the aforementioned method and the results obtained, the macrophage polarization model in BMDMs cells was established to further evaluate the function of bilobalide. As shown in [**Figure 2**](#f2){ref-type="fig"}, messenger RNA (mRNA) and protein expression of IL-1β, IL-6, and TNF-α in M1-polarized BMDMs cells were inhibited by bilobalide in a dose-dependent manner. Further, bilobalide treatment dose-dependently decreased the positive cells of MHC-II and CD11c (M1-macrophages markers) ([**Figure 3**](#f3){ref-type="fig"}). Overall, these results demonstrated the anti-inflammatory effect of bilobalide was due to the inhibition of differentiation of M1-polarized macrophages.

![Bilobalide inhibited the cytokines expression of M1 macrophage. **(A)** Bone marrow-derived macrophages (BMDMs) were cultured with 1, 3, and 10 μM bilobalide in the absence or presence of 10 ng/ml lipopolysaccharide (LPS) and 10 ng/ml interferon-gamma (IFN)-γ (M1) for 6 h. The messenger RNA (mRNA) expression level of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 were determined by quantitative PCR (QPCR). **(B)** BMDMs cells were treated with 3, 10, and 30 μM bilobalide in the presence of 10 ng/ml LPS and 10 ng/ml IFN-γ (M1) for 12 h. Cytokines level, IL-1β, IL-6, and TNF-α in the medium were assessed by ELISA. Data represented the mean ± SEM of three independent experiments in triplicate. \*P \< 0.05 and \*\*P \< 0.01 compared with LPS and IFN-γ group.](fphar-11-00718-g002){#f2}

![Bilobalide inhibited differentiation of M1 macrophage. **(A**, **B)** Bone marrow-derived macrophages (BMDMs) were treated with 1, 3, and 10 μM bilobalide in the presence of 10 ng/ml lipopolysaccharide (LPS) and 10 ng/ml interferon-gamma (IFN-γ) (M1) for 12 h. The expressions of major histocompatibility complex II (MHC-II) and CD11c were analyzed through flow cytometry. Data was summarized as a histogram of mean ± SEM of three independent experiments. \*P \< 0.05 and \*\*P \< 0.01 compared with LPS and IFN-γ group.](fphar-11-00718-g003){#f3}

Bilobalide Hampered Differentiation of M1 Macrophage *via* Inhibiting NF-κB Signaling {#s3_3}
-------------------------------------------------------------------------------------

The canonical NF-κB pathway has been recognized as a crucial transcription factor in regulating macrophage polarization ([@B18]). In the following experiments, STAT1 and NF-κB signaling pathways were examined. The result indicated that p65 phosphorylation was significantly inhibited, whereas the phosphorylated STAT1 was not altered by bilobalide treatment ([**Figure 4A**](#f4){ref-type="fig"}). In order to further assess the activation of p65, the location of p65 was examined by cellular components isolation and immunofluorescence. As shown in [**Figure 4B**](#f4){ref-type="fig"}, under normal condition, most of p65 was located in the cytosol. After stimulation, p65 translocation into nucleus was markedly inhibited by bilobalide treatment. Besides, the immunofluorescence analysis also confirmed that the bilobalide treatment could obviously inhibit the accumulation of NF-κB p65 in the nuclei of BMDMs ([**Figure 4C**](#f4){ref-type="fig"}). Altogether, these results verified that bilobalide could inhibit the NF-κB signaling and thereby hampered differentiation of M1 macrophage.

![Bilobalide inhibited NF-κB signaling which hampered differentiation of M1 macrophage. **(A)** Bone marrow-derived macrophages (BMDMs) were treated with 1, 3, and 10 μM bilobalide in the presence of 10 ng/ml lipopolysaccharide (LPS) and 10 ng/ml interferon-gamma (IFN-γ) (M1) for 30 min. The expression of MyD88, TRAF6, p-STAT1, STAT1, p-p65, and p65 were determined by western blot. **(B)** BMDMs were treated with 10 μM bilobalide in the presence of 10 ng/ml LPS and 10 ng/ml IFN-γ (M1) for 30 min. The cytosol and nuclei fraction were isolated and the level of p65 was determined by western blot. **(C)** The BMDMs were cultured as described above and stained with p65. The nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI) (blue). Scale bar: 10 μm.](fphar-11-00718-g004){#f4}

Bilobalide Ameliorated Dextran Sulfate Sodium-Mediated Colitis in Mice {#s3_4}
----------------------------------------------------------------------

The therapeutic potential of bilobalide on acute colitis was then detected in DSS-induced experimental colitis model. It was observed that the body weight of the mice substantially decreased after DSS administration compared with the normal group (drinking water) ([**Figure 5A**](#f5){ref-type="fig"}). However, compared with the DSS group, body weights of the mice were improved significantly when they were treated with bilobalide ([**Figure 5A**](#f5){ref-type="fig"}). Additionally, cumulative DAI, which is usually applied as surrogate of degree of disease development, reduced markedly in DDS + bilobalide group compared with DSS group ([**Figure 5B**](#f5){ref-type="fig"}). Notably, the administration of DSS resulted in remarkable decrease in the length of the colon, whereas bilobalide treatment significantly improved the contractible of the colon ([**Figures 5C, D**](#f5){ref-type="fig"}). However, the 5-aminosalicylic acid (5-ASA) had no obvious influence on the colon length in comparison with the DSS challenged mice. Collectively, these results demonstrate that bilobalide could improve the severity of colitis in DSS-induced colitic mice, which may probably be attributed to the anti-inflammatory properties of bilobalide.

![Bilobalide alleviated dextran sulfate sodium (DSS)-induced experimental colitis. **(A)** The body weight of mice was measured and presented as a percentage of the original body weight. **(B)** The calculated disease activity index. **(C)** Photograph of colon. **(D)** Length of colon when the mouse is sacrificed. Values were presented as mean ± SEM of 6 mice/group. \*P \< 0.05, \*\*P \< 0.01 compared with DSS-treated group.](fphar-11-00718-g005){#f5}

Effect of Bilobalide on Histological Alteration {#s3_5}
-----------------------------------------------

In order to further confirm the colitis improvement achieved by bilobalide, histological results are presented in [**Figure 6**](#f6){ref-type="fig"}. According to the degree of inflammatory cells infiltration, the colon inflammation was divided into five levels. There was no inflammatory cells in the normal mucosa, submucosal, muscularis propria, and serosa in normal group. Instead, multiple large ulcers with transmural inflammation, necrosis of the entire wall or part of it, massive depletion of crypt, goblet cells, and infiltration of inflammatory cells, e.g., neutrophils and eosinophils were observed in DSS challenged mice. The pathological changes with the administration of bilobalide demonstrated relatively low histological injury score compared with the DSS group ([**Figures 6A, B**](#f6){ref-type="fig"}). The levels of myeloperoxidase (MPO) activity in the colon tissue of DSS-induced mice are shown in [**Figure 6C**](#f6){ref-type="fig"}. The increased activity of MPO could mainly be attributed to the DSS administration in the colon tissue compared with the normal group. MPO, as a kind of hemeprotein is mainly present in eosinophilic granules of neutrophils and is used as an indirect measure of the intensity of tissue inflammation. As shown in [**Figure 6C**](#f6){ref-type="fig"}, the MPO activity was obviously decreased at 2.5 and 5 mg/kg group in comparison with the DSS group. The 5-ASA treated group had a relatively poorly inhibitory effect on MPO positive cells compared with the DSS group. Overall, these findings showed that bilobalide could effectively relieve symptoms of colitis effectively in mice like bloody diarrhea and MPO expression in the acute phase of colitis in colonic tissue.

![Bilobalide alleviated dextran sulfate sodium (DSS)-induced colon damage in mice. **(A**, **B)** Light microscopy assessment of paraffin section of colon tissue after H & E staining. Scale bar: 50 μm. **(C)** The myeloperoxidase (MPO) activity in colonic tissue was examined. Values were mean ± SEM of 6 mice/group. \*P \< 0.05, \*\*P \< 0.01 compared with DSS-treated group.](fphar-11-00718-g006){#f6}

Effect of Bilobalide on Cytokine Levels and NF-κB Activation {#s3_6}
------------------------------------------------------------

To examine whether the improvements in colitis were associated with decreased inflammation, we subsequently analyzed the expression of cytokines. As indicated in [**Figure 7A**](#f7){ref-type="fig"}, the mRNA expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in DSS mice increased significantly compared with the normal mice. The changes in cytokine levels were obviously diminished compared with the DSS control group when bilobalide (5 mg/kg) was administered. Next, ELISA was applied to evaluate the serum levels of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. As depicted in [**Figure 7B**](#f7){ref-type="fig"}, these cytokines were increased in DSS group comparable to the normal group. Meanwhile, treatment with high dose bilobalide demonstrated a substantial reduction in the levels of TNF-α, IL-6, and IL-1β compared with the DSS group. More importantly, it was observed that the cytokines were declined slightly n 5-ASA group. Likewise, the lower dose of bilobalide (1.25 mg/kg) had no obvious influence on the levels of cytokines. Also, western blot assay showed that bilobalide also decreased the phosphorylation of p65 in the colons of DSS-induced group ([**Figures 7C, D**](#f7){ref-type="fig"}), coincidently with the data *in vitro*. Thus, this work strongly indicates that the suppression of NF-κB signaling activation may induce the anti-ulcerative colitis effect of bilobalide. Altogether, these results demonstrated that bilobalide may alleviate DSS-induced colitis. Therefore, the relationship between the protective effect of bilobalide in colitic mice and its inhibition in M1-induced inflammation was in agreement.

![Bilobalide inhibited M1 macrophage differentiation in dextran sulfate sodium (DSS)-induced colitis in mice. **(A)** Quantitative determination of mRNA expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in colon tissue. **(B)** TNF-α, IL-1β, and IL-6 in serum were measured by ELISA. Values were presented as mean ± SEM of 6 mice/group. \*P \< 0.05, \*\*P \< 0.01 compared with DSS-treated group. **(C**, **D)** The p-p65 expression in colon tissue were examined by western blotting and immunohistochemistry (IHC). Scale bar: 50 μm.](fphar-11-00718-g007){#f7}

Discussion {#s4}
==========

Pathologically, IBD is a chronic inflammatory disease of the gastrointestinal tract. It is a well-established risk factor of colorectal cancer and has a high prevalence worldwide. Macrophages have an important role in the pathogenesis of IBD. Natural products have drawn lots of attentions for their possible therapeutic activities. Bilobalide is a sesquiterpenoid lactone from *G. biloba.* Herein, the anti-colitic activity and possible mechanism was examined in this study.

Firstly, we evaluated the *in vivo* anti-inflammatory activity of bilobalide. Bilobalide decreased both them RNA and protein levels of pro-inflammatory factors in concentration dependent manner. To confirm the underlying mechanism of bilobalide, we measured the phosphorylation levels of two transcription factors (STAT1 and p65). The results suggested that bilobalide exerted a more significant inhibition on p65, relative to that of STAT1. Based on this result, we therefore propose that bilobalide mainly modulated the p65 signaling pathway rather than that of the STAT1 pathway.

Based on the results from the *in vitro* experiments using (cell line model), we further comprehensively evaluated the *in vivo* anti-inflammatory activity of bilobalide in DSS-induced colitis model. Bilobalide significantly ameliorated the DSS-induced loss of bodyweight, colon shortening, and colonic inflammation. The pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β have been shown to exhibit potential efficacy against the pathogenesis of IBD ([@B29]). Available literatures has also confirmed that pro-inflammatory cytokines interaction with the intestinal mucosal immune system at the intestinal interface may culminate in the disruption of tight junction proteins and impact intestinal homeostasis ([@B2]). Meanwhile, the characteristics of colitis coupled with many other chronic inflammatory diseases are characterized with the production of more pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α in serum and tissue ([@B28]). Also, bilobalide significantly reduced M1-type mRNA expression.

The polarization of macrophages which is responsible for the activation of macrophages activate a range of signal pathways to elicit changes in gene expression coupled with promotion of the corresponding functional properties. This phenomenon usually occurs when the microenvironment alters, and it is coordinated by a large range of mediators and regulators ([@B35]; [@B24]) but stimulated by different inducers. Microbial components like LPS, interact with toll-like receptor 4 (TLR4) to skew macrophages to the proinflammatory phenotype *via* the NF-κB signal pathway ([@B19]). The NF-κB modulates a diverse spectrum of biological processes and operates as a central regulator of inflammation ([@B39]; [@B42]). The NF-κB signaling cascade has been well studied in IBD treatment and is often dysregulated in patients, resulting in aberrant cytokine and chemokine production in the gut ([@B48]; [@B5]). Inflammation and carcinogenesis have been associated with NF-κB signaling ([@B13]). The activation of the NF-κB signaling pathway triggers an important inflammatory response, which is closely related to colorectal tumorigenesis ([@B46]). Existing literature has reviewed that the anti-inflammatory effects of some drugs against DSS-induced colitis models are *via* the inhibition of NF-κB signaling pathway ([@B7]; [@B53]; [@B56]). The activation of NF-κB signal pathway was suppressed by bilobalide based on the studied mechanisms. However, the exact proteins targeted by bilobalide still need further investigation.

In summary, bilobalide has been proved to be a low cellulotoxic and strong anti-inflammatory agent. Its ability to restraining M1 macrophage polarization by hampering the NF-κB pathways was manifested *in vitro* and *in vivo*, suggesting a potential use of bilobalide as therapeutic option for in anti-inflammation therapy.
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